The results demonstrated that pharmacological inhibition of PDE10A using PF-2545920, particularly in combination with the PDE5 inhibitor MY-5445 and multidrug resistance-associated protein 1 inhibitor reversan, leads to synergistic suppression of GBM cell proliferation in vitro, suggesting a promising low-toxicity therapeutic strategy (224). Here, PDE10A is linked to glioblastoma.